Insights from 2023 ASCO® Annual Meeting
J

ASCO® 2023 Insights: "Rates of CRS and ICANS From CIBMTR Data on US Subjects With Lymphoma Following CAR-T"

By Insights from 2023 ASCO® Annual Meeting FEATURING John DiPersio
By Insights from 2023 ASCO® Annual Meeting FEATURING John DiPersio
573 views
June 20, 2023
Comments 1
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Recommended

AUTOPLAY
16:57

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

1.2K views

·

4 months ago
22:11

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

543 views

·

4 months ago
13:07

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

816 views

·

8 months ago
27:47

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

646 views

·

6 months ago
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

876 views

·

6 months ago
16:34

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

612 views

·

5 months ago
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

357 views

·

1 month ago
17:24

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

214 views

·

1 month ago
35:27

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

696 views

·

8 months ago
20:34

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

328 views

·

3 months ago
10:04

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

477 views

·

8 months ago
14:34

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

384 views

·

4 months ago
20:18

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

505 views

·

8 months ago
08:23

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Total Health

J. Chandler, B. Randolph, M. Onciu

214 views

·

8 months ago
09:18

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Randomized …

Insights from 2023 ASCO® Annual Meeting

J. Westin

1.5K views

·

1 year ago
45:27

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

258 views

·

1 month ago
30:07

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

324 views

·

5 months ago
29:26

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

301 views

·

5 months ago
28:33

The Truth About Current Consensus Statements on Hematopoietic Cell T…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

507 views

·

8 months ago
33:48

State of the Art and Next Questions: B-Cell Lymphoma

SOHO Highlights: State of the Art and Next Questions

L. Nastoupil

428 views

·

7 months ago